England’s NICE Leads Global Effort On Surrogate Endpoints For Cost-Effectiveness

Health technology assessment bodies in England, the US, Canada, Australia, the Netherlands and Colombia have joined forces to produce guidance for drug developers on using surrogate endpoints for cost-effectiveness analyses.

(Shutterstock)

An international working group led by England’s health technology assessment (HTA) agency NICE has produced best practice guidance for drugmakers on how to select surrogate endpoints and check that these are suitable for evidence submissions in the context of cost-effectiveness.

In addition to NICE, the working group included Canada’s drug and health technologies agency (CDA-AMC), the US Institute for Clinical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Health Technology Assessment

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Canada Unveils Draft List of Essential Drugs For Universal Pharmacare

 

The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.

More from R&D

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By 

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

Bayesian Statistics In EU Clinical Trials: EMA Discusses Balancing Efficiency With Rigor

 

Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.

Korea Pre-Review Consultations Help Accelerate R&D

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.